heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analog of the tetrapeptide tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Reported consistently across pharmacopoeial descriptions |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| Solubility | Freely soluble in water | Aqueous buffers; poor in nonpolar solvents |
| Typical storage temperature | -20 degrees Celsius | Lyophilized powder; protect from moisture |
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
== Malignant neoplasm of lip, oral cavity, and pharynx (140–149) == 140 Malignant neoplasm of lip 141 Malignant neoplasm of tongue 142 Malignant neoplasm of major salivary glands 143 Malignant neoplasm of gum 144 Malignant neoplasm of floor of mouth 145 Malignant neoplasm of other and unspecified parts of mouth 146 Malignant neoplasm of oropharynx 147 Malignant neoplasm of nasopharynx 148 Malignant neoplasm of hypopharynx 149 Malignant neoplasm of other and ill-defined sites within the lip
=== Fructose metabolism === Fructose must undergo certain extra steps in order to enter the glycolysis pathway. Enzymes located in certain tissues can add a phosphate group to fructose. This phosphorylation creates fructose-6-phosphate, an intermediate in the glycolysis pathway that can be broken down directly in those tissues. This pathway occurs in the muscles, adipose tissue, and kidney. In the liver, enzymes produce fructose-1-phosphate, which enters the glycolysis pathway and is later cleaved into glyceraldehyde and dihydroxyacetone phosphate.
=== Characterisation and family === After his first scenes aired, Kipa-Williams wrote a detailed biography from his character's perspective on social media. He revealed that Ari's full name is Ariki Wiremu Parata, and that he moved to Australia from New Zealand twelve years prior to his debut appearance. He continued: "I've had a few challenges and those challenges brought me to Summer Bay... I love my whanau (family), I'll do anything for them, but never cross me. I didn't know the guy who died but my heart goes out to the family. As for me, I guess you'll find out if I stay in the bay or if I go when Home and Away returns in 2020." The character's profile on TVNZ confirmed that Ari had served time in prison, which he tries to keep to himself. Kipa-Williams revealed that Ari was involved in "a life of crime", but made the decision to change and leave it behind him. However, "he wrestles with his past" and is constantly "frustrated" with the few opportunities available to him because of his criminal record. Ari is "fiercely protective" of the family, especially since his brother's death, and he has become the patriarch of the family. Although this has left him feeling "a little out of his depth". Ari dislikes confrontation and he struggles to express his emotions, but he is keen to change "his path." Kipa-Williams stated "he has made some strong choices but he is a little bit lost.
Sources: en.wikipedia.org
Insect-based pet food is pet food consisting of, or containing insects digestible by pets such as dogs or cats. A limited, but growing number of products are available on the market, including insect-based cat food, dog food, and pet treats. The process of consuming insects by animals (as well as humans) is called entomophagy.
==== Proton abstraction ==== Proton abstraction is different from the three ionization methods mentioned above because negative ions (NI) are formed during the process rather than positive ions. (M-H)− ions are often produced in polar organics in the NI mode. The first three ionization mechanisms discussed above all have their analogues in NI-FD-MS. In field ionization, molecular anions (M− ̇ ) can be generated. Anion attachment can also lead to the formation of negative ions for some molecules, for example, (M + Cl)−. Thermal desorption usually produces anion (A−) and cluster ion (e.g. CA2−) for salts.
On 19 March 2015, troops loyal to Hadi clashed with those who refused to recognize his authority in the Battle of Aden Airport. The forces under General Abdul-Hafez al-Saqqaf were defeated, and al-Saqqaf fled toward Sanaa. In apparent retaliation for the routing of al-Saqqaf, warplanes reportedly flown by Houthi pilots bombed Hadi's compound in Aden. After the 20 March 2015 Sanaa mosque bombings, in a televised speech, Abdul-Malik al-Houthi, the leader of the Houthis, said his group's decision to mobilize for war was "imperative" under current circumstances and that Al-Qaeda in the Arabian Peninsula and its affiliates—among whom he counts Hadi—would be targeted, as opposed to southern Yemen and its citizens. President Hadi declared Aden to be Yemen's temporary capital while Sanaa remained under Houthi control. Also, the same day as the mosque bombings, al-Qaeda militants captured the provincial capital of Lahij, Al Houta District after killing about 20 soldiers before being driven out several hours later. Hadi reiterated in a speech on 21 March 2015 that he was the legitimate president of Yemen and declared, "We will restore security to the country and hoist the flag of Yemen in Sanaa, instead of the Iranian flag." He also declared Aden to be Yemen's "economic and temporary capital" due to the Houthi occupation of Sanaa, which he pledged would be retaken. In Sanaa, the Houthi Revolutionary Committee appointed Major General Hussein Khairan as Yemen's new defence minister and placed him in overall command of the military offensive.
The plutonium present in spent nuclear fuel contains about 12% of 241Pu. Because it converts to 241Am, 241Pu can be extracted and may be used to generate further (isotopically pure) 241Am. However, this process is rather slow: half of the original amount of 241Pu decays to 241Am after about 14 years, and the 241Am amount reaches a maximum after 70 years. The obtained 241Am can be used for generating heavier americium isotopes by further neutron capture inside a nuclear reactor. In a light water reactor (LWR), 79% of neutron captures on 241Am convert to 242Am and 10% to its nuclear isomer 242mAm:
Sources: en.wikipedia.org
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.
The first four residues of Selank reproduce the tuftsin sequence Thr-Lys-Pro-Arg. A Pro-Gly-Pro extension at the C-terminus was added to slow enzymatic breakdown and extend residence time.
It holds marketing authorization in Russia, where nasal drop formulations are sold. No equivalent approval exists in the European Union, the United States, or most other countries.
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.